Cargando…
A Therapeutic Approach to Nasopharyngeal Carcinomas by DNAzymes Targeting EBV LMP-1 Gene
Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) has been known to have oncogenic properties during latent infection in nasopharyngeal carcinoma (NPC). Genetic manipulation of LMP1 expression may provide a novel strategy for the treatment of NPC. DNAzymes are synthetic, single-stran...
Autores principales: | Yang, Lifang, Lu, Zhongxin, Ma, Xiaoqian, Cao, Ya, Sun, Lun-Quan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257677/ https://www.ncbi.nlm.nih.gov/pubmed/20877211 http://dx.doi.org/10.3390/molecules15096127 |
Ejemplares similares
-
EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinoma
por: Yang, Lifang, et al.
Publicado: (2015) -
Correction: Yang L, et al., “Targeting EBV-LMP1 DNAzyme enhances radiosensitivity of nasopharyngeal carcinoma cells by inhibiting telomerase activity”, Cancer Biol Ther 2014; 15:61–8
por: Yang, Lifang, et al.
Publicado: (2014) -
Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma
por: Kamara, Saidu, et al.
Publicado: (2023) -
Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma
por: Zhu, Shanli, et al.
Publicado: (2020) -
HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer
por: Lifang, Yang, et al.
Publicado: (2008)